Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate

References

• Arbeitgemeinschaft für Methodik und Dokumentation in der Psychiatrie. 2006. Das AMDP-System. 8. überarbeitet Auflage. Göttingen: Hogrefe.
   Google Scholar
• Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherswon P, Buitelaar J, . 2006. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry 15:476–495.
   PubMed Web of Science ®Google Scholar
• Barkley RA, Murphy KR. 1998. Attention-deficit hyperactivity disorder. A clinical workbook. New York: Guilford.
   Google Scholar
• Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD. 2000. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 176:421–428.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, . 2006. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829–835.
   PubMed Web of Science ®Google Scholar
• Bradley C. 1937. The behaviour of children receiving benzedrine. Am J Psychiatry 94:577–585.
   Google Scholar
• Conners CK, Erhardt D, Sparrow E. 1999. CAARS Conners Adult ADHD Rating Scales. New York: MHS.
   Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. 1998. ADHD Rating Scale – IV. New York: Guilford.
   Google Scholar
• Ebert D, Krause J, Roth-Sackenheim C and the DGPPN Expert Committee. 2003. [ADHD in adulthood–-guidelines based on expert consensus with DGPPN support.] Nervenarzt 74:939–946.
   PubMedGoogle Scholar
• Edel MA, Pfütze EM, Lieder A, Assion HJ, Ribbert H, Juckel G, Brüne M. 2009. Self-concept, action control and ADHD symptoms under methylphenidate treatment in adults with ADHD. Pharmacopsychiatry 42:109–113.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Glatt SJ. 2010. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71: 754–763.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. 2004. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24:24–29.
   PubMed Web of Science ®Google Scholar
• Fayyad J, De Graf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, . 2007. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402–409.
   PubMed Web of Science ®Google Scholar
• García-García P, López-Muñoz F, Molina JD, Fischer R, Alamo C. 2009 Methylphenidate extended-release capsules: a new formulation for attention-deficit hyperactivity disorder. Front Drug Des Discov 4:228–246.
   Google Scholar
• Gibbins C, Weiss M. 2007. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep 9:420–426.
   PubMedGoogle Scholar
• Goodman DW. 2007. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract 13:318–327.
   PubMedGoogle Scholar
• Guy W, Ban TA. 1982. The AMDP System. A manual for the assessment and documentation in psychopathology. Berlin: Springer.
   Google Scholar
• Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S. 2009. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744.
   PubMed Web of Science ®Google Scholar
• Marchant BK, Reimherr FW, Robison RJ, Olsen JL, Kondo DG. 2010. Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord [epub ahead of print].
   Google Scholar
• Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. 2009. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12:1137–1147.
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, . 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53: 112–120.
   PubMed Web of Science ®Google Scholar
• Murphy P, Schachar R. 2000. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 157:1156–1159.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. 2008. Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults [www.NICE.org.uk.].
   Google Scholar
• NIMH. 1985. CGI (Clinical Global Impression) scale. Psychopharmacol Bull 21:839–843.
   Google Scholar
• Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, . 2007. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21:10–41.
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, . 2005. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 58:125–131.
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. 2007. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93–101.
   PubMed Web of Science ®Google Scholar
• Retz-Junginger P, Retz W, Blocher D, Weijers HG, Trott GE, Wender PH, Rösler M. 2002. [Wender Utah rating scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults.] Nervenarzt 73:830–808.
   PubMed Web of Science ®Google Scholar
• Retz-Junginger P, Retz W, Blocher D, Stieglitz RD, Georg T, Supprian T, . 2003. [Reliability and validity of the Wender-Utah-Rating-Scale short form. Retrospective assessment of symptoms for attention deficit/hyperactivity disorder.] Nervenarzt 74:987–993.
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Retz-Junginger P, Thome J, Supprian T, Nissen T, . 2004. [Tools for the diagnosis of attention-deficit/hyperactivity disorder in adults. Self-rating behaviour questionnaire and diagnostic checklist.] Nervenarzt 75:888–895.
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Thome J, Schneider M, Stieglitz R-D, Falkai P. 2006. Psychopathological rating scales for diagnostic use in adults with attention deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 256(Suppl1):3–11.
   Google Scholar
• Rösler M, Retz W, Retz-Junginger P, Stieglitz RD, Reimherr F, Wender P. 2008a. [Attention deficit-/hyperactivity disorder (ADHD) in adults: benchmarking diagnosis using the Wender-Reimherr Adult ADHD Rating Scale (WRAADDS).] Nervenarzt 79:320–327.
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Retz-Junginger P, Stieglitz RD, Reimherr F, Wender P. 2008b. Homburger ADHS Skalen für Erwachsene (HASE). Göttingen: Hogrefe.
   Google Scholar
• Rösler M, Fischer R, Ammer R, Ose C, Retz W. 2009. A randomised, placebo-controlled, 24–week, study of low dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120–129.
   PubMed Web of Science ®Google Scholar
• Rösler M, Casas M, Konofal E, Buitelaar J. 2010a. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 11:684–698.
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, . 2010b. Twenty-for-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 11:709–718.
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Stieglitz RD. 2010c. Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations – benchmarking instruments for international multicentre trials. Pharmacopsychiatry 43:92–98.
   PubMed Web of Science ®Google Scholar
• Sheehan DV. 1983. The anxiety disease. New York: Scribner.
   Google Scholar
• Sheehan KH, Sheehan DV. 2008. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23:70–83.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Adler LA, Weisler RH, Youcha SH. 2008. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 69:1437–1448.
   PubMed Web of Science ®Google Scholar
• Stein MA. 2004. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care 10:S89–98.
   PubMed Web of Science ®Google Scholar
• Weiss MD, Gibbins C, Goodman DW, Hodgkins PS, Landgraf JM, Faraone SV. 2010. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J Clin Psychiatry 71:381–390.
   PubMed Web of Science ®Google Scholar
• Wender PH. 1995. Attention-deficit hyperactivity disorder in adults. New York: Oxford University Press.
   Google Scholar
• Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA. 2010. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord, [epub ahead of print].
   Google Scholar
• Wittchen H-U, Zaudig M, Fydrich T. 1997. SKID-I und SKID-II Strukturiertes Klinisches Interview für DSM-IV (1997). Göttingen: Hogrefe.
   Google Scholar